Search Results - "Sapin, H."

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy by Pöhlmann, J., Norrbacka, K., Boye, K. S., Valentine, W. J., Sapin, H.

“…Background Health economic evaluations require cost data as key inputs. Many countries do not have standardized reference costs so costs used often vary…”
Get full text

Proportion of patients with osteoporosis in postmenopausal women performing a bone mineral density diagnosis measurement: The presage study by Guggenbuhl, P, Dufour, R, Liu-Leage, S, Sapin, H, Cortet, B

Get full text

Suivi sur 5 ans des patients adultes déficitaires en hormone de croissance traités par Umatrope®  : données de l’observatoire français des prescriptions d’Umatrope by Benabbad, I, Touraine, P, Delemer, B, Chartier, F, Sapin, H

“…Décrire les caractéristiques des patients adultes déficitaires en hormone de croissance (GHD) traités par Umatrope® en France. Étude observationnelle…”
Get full text

PDB49 Resource Use in Patients with Type 2 Diabetes (T2D) Who Initiated Exenatide BID (EXBID) or Starter Insulin (INS) Therapy: 6-Month Data from Choice by Theodorakis, M, Reaney, M.D, Bruhn, D, Matthaei, S, Mathieu, C, Kiljanski, J, Guerci, B, Sapin, H, Östenson, C.G, Salaun-Martin, C, Krarup, T

Get full text

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries by Ostenson, Claes-Göran, Matthaei, Stephan, Reaney, Matthew, Krarup, Thure, Guerci, Bruno, Kiljanski, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Bruhn, David, Mathieu, Chantal, Theodorakis, Michael

“…The CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy (CHOICE) study assessed time to, and reasons for,…”
Get full text

P.2.e.036 Determination of a Young Mania Rating Scale severity threshold and of the minimally clinical significant difference in the EMBLEM cohort by Lukasiewicz, M, Gerard, S, Besnard, A, Falissard, B, Perrin, E, Sapin, H, Tohen, M, Reed, C, Azorin, J.M

Get full text

IDF2022-0371 Decreased HbA1c levels associated with improved patient reported outcomes in T2D patients treated with tirzepatide by Thieu, V., Boye, K.S., Lee, C., Sapin, H.

Get full text

IDF2022-0372 Higher weight loss is associated with improved patient reported outcomes in T2D patients treated with tirzepatide by Boye, K.S., Thieu, V., Lee, C., Sapin, H.

Get full text

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study by Kiiskinen, Urpo, Matthaei, Stephan, Reaney, Matthew, Mathieu, Chantal, Ostenson, Claes-Göran, Krarup, Thure, Theodorakis, Michael, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Guerci, Bruno

“…CHOICE (CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy) assessed patterns of exenatide bid and initial…”
Get full text

PCR202 Estimating Meaningful Change for the Impact of Weight on Self-Perception (IW-SP) Questionnaire Among People with Type 2 Diabetes by Gelhorn, H., Maher, S., Sapin, H., Poon, J.L., Boye, K.

Get full text

P301 Utilisation des ressources de santé par des patients avec diabète de type 2 initiant un traitement par exénatide 2 fois par jour ou une insulinothérapie : données à 6 mois de l’étude CHOICE by Guerci, B, Sapin, H, Östenson, C.-G, Krarup, T, Theodorakis, M, Reaney, M, Brunh, D, Kiljanskihn, J, Salaun-Martin, C, Matthaei, S, Simon, C

“…Objectif Description de l’utilisation des ressources de santé durant les 6 mois précédant et suivant l’initiation d’un traitement injectable du diabète de type…”
Get full text

P304 - Conditions d’utilisation de la duloxétine en France : étude pharmaco-épidémiologique observationnelle, prospective et transversale by Pechtner, V, Picard, H, Tcherny, S, Arkoub, H, Sapin, H, Augendre-Ferrante, B, Rouillon, F, Perrot, S, Valensi, P

“…Rationnel Dans le contexte du plan de gestion des risques de la duloxétine (3 indications : trouble dépressif majeur, trouble anxiété généralisée et douleur…”
Get full text

POSC359 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Reported Outcomes at 12-Months by Boye, K, Lebrec, J, Sapin, H, Guerci, B, Giorgino, F, Füchtenbusch, M, Heitmann, E, Orsini Federici, M, Dib, A, García-Pérez, LE

Get full text

PDB3 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 6-Month Analysis Results by Giorgino, F., Guerci, B., García-Pérez, L.E., Boye, K., Aigner, U., Heitmann, E., Orsini Federici, M., Zimner-Rapuch, S., Rosilio, M., Norrbacka, K., Sapin, H.

Get full text

PDB113 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): PATIENT-REPORTED OUTCOMES AT BASELINE by Boye, K., García-Pérez, L.E., Sapin, H., Rosilio, M., Orsini Federici, M., Heitmann, E., Jung, H., Gentilella, R., Aigner, U., Guerci, B., Giorgino, F., Norrbacka, K.

Get full text

PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS by García-Pérez, L.E., Sapin, H., Norrbacka, K., Guerci, B., Giorgino, F., Aigner, U., Orsini Federici, M., Gentilella, R., Heitmann, E., Jung, H., Rosilio, M., Boye, K.

Get full text

PDB82 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE AND LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): COUNTRY-SPECIFIC BASELINE CHARACTERISTICS by Sapin, H., García-Pérez, L.E., Norrbacka, K., Giorgino, F., Guerci, B., Aigner, U., Orsini Federici, M., Gentilella, R., Heitmann, E., Jung, H., Rosilio, M., Boye, K.

Get full text

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study by Reaney, Matthew, Mathieu, Chantal, Ostenson, Claes-Göran, Matthaei, Stephan, Krarup, Thure, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Theodorakis, Michael, Guerci, Bruno

“…Improvements in the clinical condition of patients with type 2 diabetes are often accompanied by improvements in health-related quality of life and other…”
Get full text

Suivi sur 5ans des patients adultes déficitaires en hormone de croissance traités par Umatrope® : données de l’observatoire français des prescriptions d’Umatrope by Benabbad, I., Touraine, P., Delemer, B., Chartier, F., Sapin, H.

Get full text

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE by Mathieu, Chantal, Östenson, Claes-Göran, Matthaei, Stephan, Reaney, Matthew, Krarup, Thure, Guerci, Bruno, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Theodorakis, Michael

“…Introduction CHOICE (CHanges to treatment and Outcomes in patients with type 2 diabetes initiating InjeCtablE therapy; NCT00635492) assessed, as its primary…”
Get full text